Purpose: To assess the sensitivity of two commercial dosimetry systems in detecting Helical TomoTherapy (HT) delivery errors.
Method: Two commercial dosimeters i) MatriXX and ii) ArcCHECK® were considered. Ten retrospective nasopharynx HT patients were analysed. For each patient, error plans were created by independently introducing systematic offsets in: a) Jaw width error ±1, ±1.5 and ±2mm, b) Couch speed error ±2%, ±2.5, ±3% and ±4%, and c) MLC Leaf Open Time (MLCLOT) errors (3 separate MLC errors: either leaf 32 open or leaf 42 remains open during delivery, and 4% random reductions in MLCLOT). All error plans, along with the no error plan for each patient, were measured using both dosimeters in the same session. Gamma evaluation (3%/3mm) was applied to quantitatively compare the measured dose from each dosimeter to the treatment planning system. The error sensitivity was quantified as the rate of decrease in gamma pass rate.
Results: The gamma pass rate decreases with increase in error magnitude for both dosimeters. ArcCHECK was insensitive for couch speed error up to 2.5% and jaw width error up to -1.5mm while MatriXX was found to be insensitive to couch speed error up to 2% and couch speed up to -1mm. Both of the detectors show similar sensitivity to all the MLCLOT errors that were clinically relevant.
Conclusion: No statistically significant (p>0.05) differences exist in detecting the simulated delivery errors between MatriXX and ArcCHECK dosimeter systems for HT plans. Both dosimeters were able to pick up clinically relevant delivery errors.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejmp.2017.04.011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Patient-Specific CBCT Synthesis for Real-time Tumor Tracking in Surface-guided Radiotherapy.
ArXiv
November 2024
Department of Radiation Oncology and Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA.
In this work, we present a new imaging system to support real-time tumor tracking for surface-guided radiotherapy (SGRT). SGRT uses optical surface imaging (OSI) to acquire real-time surface topography images of the patient on the treatment couch. This serves as a surrogate for intra-fractional tumor motion tracking to guide radiation delivery.
View Article and Find Full Text PDFDevelopment of an external system for monitoring the couch speed in radiotherapy using continuous bed movement.
J Appl Clin Med Phys
November 2024
Department of Radiation Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan.
Purpose: Total body irradiation before bone marrow transplantation for hematological malignancies using Radixact, a high-precision radiotherapy machine, can potentially reduce side effects and the risk of secondary malignancies. However, stable control of couch speed is critical, and direct assessment methods outlined in quality assurance guidelines are lacking. This study aims to develop a real-time couch speed verification system for the Radixact.
View Article and Find Full Text PDFAn interface tool to parametrize treatment plans for the TrueBeam radiotherapy system into TOPAS parameter control files for Monte Carlo simulation.
Phys Med
August 2024
University of California San Francisco, Department of Radiation Oncology 1600 Divisadero Street, San Francisco, CA 94143, United States. Electronic address:
Purpose: The Monte Carlo (MC) method, the gold standard method for radiotherapy dose calculations, is underused in clinical research applications mainly due to computational speed limitations. Another reason is the time-consuming and error prone conversion of treatment plan specifications into MC parameters. To address this issue, we developed an interface tool that creates a set of TOPAS parameter control files (PCF) from information exported from a clinical treatment planning system (TPS) for plans delivered by the TrueBeam radiotherapy system.
View Article and Find Full Text PDFAdding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial.
Lancet
June 2024
MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK. Electronic address:
Article Synopsis
- A clinical trial called RADICALS-HD studied the effects of adding short-course androgen deprivation therapy (ADT) to postoperative radiotherapy in patients with localized prostate cancer after surgery.
- It involved 1480 patients, examining how ADT impacts metastasis-free survival compared to radiotherapy alone, and measured outcomes like distant metastasis and overall survival.
- The trial aimed to see if combining ADT with radiotherapy could improve the 10-year metastasis-free survival rate, potentially increasing it from 80% to 86%.
Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial.
Lancet
June 2024
MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK. Electronic address:
Article Synopsis
- The study investigates the effectiveness and optimal duration of androgen deprivation therapy (ADT) combined with postoperative radiotherapy for patients with localized prostate cancer following radical prostatectomy.
- A randomised controlled trial, RADICALS-HD, compared short-course ADT (6 months) to long-course ADT (24 months) among participants who met specific criteria, including PSA levels and absence of metastatic disease.
- The primary outcome measured was metastasis-free survival, with the trial aiming to determine if longer ADT duration leads to better survival rates, involving over 1,500 patients from 2008 to 2015.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!